tiprankstipranks
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
US Market
GALT
Galectin Therapeutics
RESEARCH TOOLSreports

Galectin Therapeutics (GALT) Income Statement

668 Followers

Galectin Therapeutics Income Statement

Last quarter (Q4 2025), Galectin Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Galectin Therapeutics's net income was $-5.50M. See Galectin Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Dec 23Dec 22Mar 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ -37.00K$ -33.00K$ -32.00K$ -41.00K
Operating Expenses
$ 20.09M$ 42.40M$ 38.04M$ 38.32M$ 30.14M
Depreciation and Amortization
$ 53.00K$ 37.00K$ 33.00K$ 32.00K$ 41.00K
EBITDA
$ -23.45M$ -41.47M$ -38.24M$ -37.71M$ -30.00M
Operating Income
$ -20.09M$ -42.43M$ -38.07M$ -38.35M$ -30.18M
Other Income/Expenses
$ -10.75M$ -4.61M$ -2.99M$ -424.00K$ -348.00K
Pretax Income
$ -30.84M$ -47.05M$ -41.07M$ -38.78M$ -30.53M
Net Income
$ -30.84M$ -47.05M$ -41.07M$ -38.78M$ -30.53M
Per Share Metrics
Basic EPS
$ -0.48$ -0.76$ -0.74$ -0.65$ -0.52
Diluted EPS
$ -0.48$ -0.76$ -0.74$ -0.65$ -0.52
Weighted Average Shares Outstanding
 63.90M 62.31M 60.16M 59.39M 58.53M
Weighted Average Shares Outstanding (Diluted)
 63.90M 62.31M 60.16M 59.39M 58.53M
Currency in USD

Galectin Therapeutics Earnings and Revenue History